Jean-Philippe O.
- Country
- France
- Department
- Pneumologie
Research Overview
- Evaluation of Tozorakimab Efficacy and Safety in Chronic Obstructive Pulmonary Disease with Exacerbation History: A Randomized, Double-Blind, Placebo-Controlled Trial
- A phase III, Multicentre, Open-Label, Chronic dosing, Extension Study to Evaluate the Long-term Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations (ROMEO)
Data & Insights
Has run more than one trial at 9 of 118 partner sites.
Specializations
Pulmonology and respiratory oncology
Jean-Philippe OSTER is involved in clinical research centered on non-small cell lung cancer, including molecularly defined disease such as BRAFV600E-mutant NSCLC and ROS1-rearranged lung cancer, as well as treatment strategies for patients with interstitial lung disease and advanced respiratory comorbidity. His work also extends to chronic obstructive pulmonary disease and the management of exacerbation-prone patients.
- Non-small cell lung cancer
- Interstitial lung disease
- Chronic obstructive pulmonary disease
- Targeted therapy in lung cancer
His therapeutic interest includes optimizing care for patients with limited respiratory reserve and integrating modern anticancer approaches in thoracic malignancies.
Gastrointestinal oncology
His clinical research landscape includes multiple gastrointestinal malignancies, with a strong focus on metastatic colorectal cancer, rectal cancer, colon cancer, pancreatic adenocarcinoma, and ampullary adenocarcinoma. He is also engaged in studies addressing obstructive colon cancer and cholangiocarcinoma.
- Metastatic colorectal cancer
- Rectal cancer
- Pancreatic adenocarcinoma
- Ampullary adenocarcinoma
His therapeutic profile reflects sustained involvement in systemic treatment strategies for digestive tract cancers, with attention to advanced and biomarker-defined disease.
Hemato-oncology and immune-mediated blood disorders
Jean-Philippe OSTER contributes to research in acute lymphoblastic leukemia, acute myeloid leukemia, and primary central nervous system lymphoma, alongside immune hematology, particularly persistent or chronic immune thrombocytopenia. His activity also touches on treatment optimization in multiple sclerosis and other immune-driven conditions.
- Acute lymphoblastic leukemia
- Acute myeloid leukemia
- Primary central nervous system lymphoma
- Immune thrombocytopenia
This area of interest links hematologic malignancies with immune modulation and long-term disease control.
Autoimmune, inflammatory, and rheumatologic diseases
His research portfolio includes rheumatoid arthritis, polymyalgia rheumatica, Crohn’s disease, ulcerative colitis, and other chronic inflammatory disorders. He is also involved in studies on multiple sclerosis and kidney transplantation patients requiring immunosuppressive management.
- Rheumatoid arthritis
- Polymyalgia rheumatica
- Crohn’s disease
- Ulcerative colitis
His therapeutic focus spans biologic therapy, immune regulation, and disease control in chronic inflammatory conditions.
Cardiovascular, neurologic, and supportive care domains
Jean-Philippe OSTER is also active in studies of out-of-hospital cardiac arrest, acute myocardial infarction, ischemic stroke, and chronic heart failure, as well as neurologic and supportive indications such as Alzheimer disease psychosis, attention deficit hyperactivity disorder, and neurogenic bladder. Additional interest includes infection-related orthopedic disease and transplant-related care.
- Out-of-hospital cardiac arrest
- Acute ischemic stroke
- Chronic heart failure
- Neurogenic bladder
His therapeutic scope includes acute care, neurologic symptom management, and complex comorbidity-focused treatment pathways.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.